[Chronic myelogenous leukemia with long-term hypoplasia induced by alpha-interferon and hydroxyurea].
A 48-year-old woman was admitted with chronic myelogenous leukemia in November, 1996 and was treated with hydroxyurea (HU), because of marked leukocytosis; WBC 404,000/microliter. On January 29, 1997, administration of HU was stopped, and treatment of alpha-interferon (IFN alpha) was started with 6x 10(6)U, every day. However, the WBC count rose from 19,600/microliter to 56,800/microliter, and the combination of IFN and 2,000 mg of HU was started on February 4. The dose of HU was reduced to 500 mg on February 27, and the IFN administration was reduced to 3 times a week from April 4, because the WBC count was less than 10,000/microliter. Pancytopenia was revealed in May. The bone marrow biopsy specimen demonstrated marked hypoplastic changes, and chromosome analysis of bone marrow cells showed Philadelphia chromosome in all 20 metaphases. Treatment was interrupted for 7 months, but hematologic parameters did not recover. There were 9 cases reported in detail with bone marrow hypoplasia induced by IFN. One patient received IFN alone and 8 patients received anti-cancer drugs before treatment of IFN. We concluded that great care must be taken for IFN treatment of CML.
Motomura
S
S
First Department of Internal Medicine, Urafune Hospital, Yokohama City University School of Medicine.
Sakai
R
R
Tomita
N
N
Fujimaki
K
K
Hattori
M
M
Fujisawa
S
S
Mohri
H
H
Takahashi
N
N
Maruta
A
A
Kodama
F
F
Okubo
T
T
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology*; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects*; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D007964:Leukocytosis / Q000139:chemically induced; D008297:Male; D008875:Middle Aged
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D006918:Hydroxyurea